

Clopidogrel (Plavix®)

Clopidogrel (Plavix®) is primarily used to prevent harmful blood clots, in order to reduce the risk for heart attack and stroke.

Jamie, based on your genetic result, clopidogrel (Plavix®) is likely to be less effective for you.

Keep in mind that both genetic and non-genetic factors may influence your response. A healthcare provider considers many factors when choosing an appropriate course of treatment. **Do not use this result to start, stop, or change any course of treatment.** Medications should always be taken as directed.

Likely less effective


clopidogrel (Plavix®)

→ [Learn more about your result](#)

Keep in mind



If you are already taking this medication, **continue your treatment as directed** unless your doctor recommends a change.



Other factors besides your genetics can also affect your body's response to this medication.



This test **does not include all possible DNA variants** that may affect your body's response to this medication.



This result **does not apply to other antiplatelet medications**, such as ticagrelor and prasugrel.

About clopidogrel

Also known as: Plavix® (Plavix® is a registered trademark of Sanofi)



Primary uses of this medication

Clopidogrel is primarily used to prevent harmful blood clots in order to reduce the risk for heart attack and stroke. It is often prescribed for people undergoing a procedure called angioplasty, also known as percutaneous coronary intervention (PCI).



How this medication works

Clopidogrel belongs to a class of medications known as antiplatelets. An antiplatelet drug works by blocking platelets (a type of blood cell) from sticking together, preventing them from forming harmful blood clots.

Clopidogrel is a prodrug, meaning it must be converted into an active form before it can work. In people whose bodies can't convert clopidogrel properly, the medication is less effective at preventing and treating harmful blood clots. For those people, treatment with clopidogrel is less likely to decrease the risk for heart attack and stroke.

Read more at: [MedlinePlus](#) [Mayo Clinic](#)

Share a summary of your Pharmacogenetics reports with a healthcare professional.

If you ever need treatment with clopidogrel, a healthcare professional like your doctor or pharmacist may be able to use this report for reference.

If you are currently taking clopidogrel, ask your healthcare provider to refer to both the Table of Pharmacogenetic Associations published by the U.S. Food and Drug Administration and the drug label when considering what actions are appropriate based on your result.

Do not use this result to start, stop, or change any course of treatment. Medications should always be taken as directed.



Print summary

Your Genetic Result

CYP2C19 Drug Metabolism

Predicted intermediate metabolizer



[View report >](#)

References

- Cavallari LH et al. (2018). "Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention." *JACC Cardiovasc Interv.* 11(2):181-191. ¹
- Claassens DMF et al. (2019). "A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI." *N Engl J Med.* 381(17):1621-1631. ²
- Dayoub EJ et al. (2018). "Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016." *JAMA Intern Med.* 178(7):943-950. ³
- Deiman BA et al. (2016). "Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands." *Neth Heart J.* 24(10):589-99. ⁴
- Klein MD et al. (2019). "Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention." *Arterioscler Thromb Vasc Biol.* 39(4):647-652. ⁵
- Lee CR et al. (2018). "Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention." *Circ Genom Precis Med.* 11(4):e002069. ⁶
- Mega JL et al. (2009). "Cytochrome p-450 polymorphisms and response to clopidogrel." *N Engl J Med.* 360(4):354-62. ⁷
- Mega JL et al. (2010). "Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis." *JAMA.* 304(16):1821-30. ⁸
- Scott SA et al. (2011). "Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy." *Clin Pharmacol Ther.* 90(2):328-32. ⁹
- Scott SA et al. (2012). "PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19." *Pharmacogenet Genomics.* 22(2):159-65. ¹⁰
- Scott SA et al. (2013). "Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update." *Clin Pharmacol Ther.* 94(3):317-23. ¹¹
- Shuldiner AR et al. (2009). "Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy." *JAMA.* 302(8):849-57. ¹²
- U.S. Food and Drug Administration (2010). "FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug." Retrieved November 1, 2019, from <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor> ¹³
- U.S. Food and Drug Administration (2020). "Table of Pharmacogenetic Associations." Retrieved December 21, 2020 from <https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations> ¹⁴
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. "Plavix® (clopidogrel bisulfate) NDA 020839 Label." Retrieved November 13, 2019, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020839s072lbl.pdf ¹⁵
- Wallentin L et al. (2009). "Ticagrelor versus clopidogrel in patients with acute coronary syndromes." *N Engl J Med.* 361(11):1045-57. ¹⁶

Change Log

Your report may occasionally be updated based on new information. This Change Log describes updates and revisions to this report.

Date	Change
May 19, 2021	Clopidogrel (Plavix®) report created.



Give the gift of DNA discovery.

Gift a kit

Refer friends, earn rewards.

Get reward

ANCESTRY

Ancestry Overview
All Ancestry Reports
Ancestry Composition
DNA Relatives
Order Your DNA Book

HEALTH & TRAITS

Health & Traits Overview
All Health & Traits Reports
My Health Action Plan
Health Predisposition
Pharmacogenetics
Carrier Status
Wellness
Traits

RESEARCH

Research Overview
Surveys and Studies
Edit Answers
Publications

FAMILY & FRIENDS

View all DNA Relatives
Family Tree
Your Connections
GrandTree
Advanced DNA Comparison